-
The price of raw materials for Lianhua Qingwen has skyrocketed, and ensuring production is the top priority!
Time of Update: 2022-12-30
According to the third quarterly report of 2022 released by Shijiazhuang Yiling Pharmaceutical Co. , Ltd. (Yiling Pharmaceutical, 002603), in the first three quarters, the company achieved operating
-
The new version of the tertiary hospital review pays close attention to illegal procurement and malicious insurance fraud!
Time of Update: 2022-12-30
Since the beginning of this year, the Central Commission for Discipline Inspection and the State Supervision Commission have repeatedly intensively reported on medical anti-corruption, drug kickbacks and other issues, and while medical representatives, pharmaceutical companies and other relevant personnel have been brought out, many "number one" in third-class hospitals have also fallen one after another.
-
Pharmaceutical companies in many places are fully powered, and the circulation of drugs is accelerated - to meet the needs of the masses for drugs to the greatest extent
Time of Update: 2022-12-30
In recent days, the demand for treatment drugs after new coronavirus infection has increased significantly. The joint prevention and control mechanism of the State Council held a press conference a f
-
In 2023, the field of innovative drugs may welcome Davis double-click, and such companies can pay attention
Time of Update: 2022-12-30
It is reported that on December 15, Innovent Biologics announced that the Group and LG Chem Life Sciences (hereinafter referred to as "LG Chem"), a subsidiary of LG Chem, have reached a strategic cooperation and licensing agreement on the late-stage clinical innovative drug Tigulixotat (LG R&D code: LC350189, Group R&D code: IBI-350), a new non-purine analogue xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia in gout patients.
-
MAH's implementation of the list of main responsibilities for drug quality has come, and the key personnel of pharmaceutical companies are trembling
Time of Update: 2022-12-30
1. What is the scope of MAH key personnel?1) The definition of key personnel in the current version of GMP in China in 2010: The key personnel of a pharmaceutical production enterprise shall be full-time personnel of the enterprise, at least including the person in charge of the enterprise, the person in charge of production management, the person in charge of quality management and the person in charge of quality authorization (Chapter 3 Institutions and Personnel Article 20).
-
On the same day, a large number of domestic pharmaceutical companies announced that new drugs were approved for clinical trials and marketing
Time of Update: 2022-12-30
Enhua Pharmaceutical On December 19, Enhua Pharmaceutical announced that it had recently received the "Drug Clinical Trial Approval Notice" for Class 1 chemical NH130 citrate tablets approved and issued by the National Medical Products Administration, and will carry out clinical trials in the near future, and the indication applied for is intended for the treatment of Parkinson's disease psychiatric (PDP).
-
The pharmaceutical sector is "hot and ice", and the valuation repair opportunity is optimistic
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];Recently, the pharmaceutical sector has performed strongly, and the "taking medicine" market has lasted for nearly two months since November, while the A-share pharmaceutical and biological sector has also recently attracted the attention of funds.
-
Zhejiang Province Centralized Drug Procurement Results Announced (with List)
Time of Update: 2022-12-30
The data shows that the total sales scale of this collection and procurement varieties in public hospitals in Zhejiang Province in 2021 exceeded 300 million yuan (in terms of common names), involving bright prorelin injection, triptorelin injection, lactulose oral liquid and other large clinical varieties, Lizhu, Shisi Yao, Luoxin Pharmaceutical and other enterprises successfully broke through.
-
Multinational pharmaceutical companies set off a wave of rare disease mergers and acquisitions, domestic pharmaceutical companies take orphan drugs to go to sea, Ascentage, Shiyao, Junshi ...
Time of Update: 2022-12-30
First, there are about 300 million patients with rare diseases in the world, and there are huge commercial interests in the market Due to the significant characteristics of small patient population, difficult drug research and development, and high cost, the rare disease track has always been a well-known "unpopular" and niche track, unlike anti-tumor, autoimmune and other popular tracks, attracting many pharmaceutical companies to compete and fight fiercely.
-
In 2022, China's innovative drug license out transactions TOP10
Time of Update: 2022-12-30
On the evening of December 6, Akeso announced that it entered into a licensing transaction cooperation with Summit for overseas rights (the United States, Europe, Japan and Canada) for PD-1/VEGF bispecific antibodies (Ewosi, AK112) with a down payment of 500 million US dollars and a total amount of up to 5 billion US dollars, which has attracted widespread attention in the industry.
-
CDE issued four announcements, including "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection"
Time of Update: 2022-12-30
The Drug Review Center of the State Food and Drug Administration issued the "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection", "Technical Guidelines for Bio
-
Novo Nordisk Shanghai signed a contract with Shanghai Pharmaceutical Holdings The cooperation will achieve another breakthrough
Time of Update: 2022-12-30
Xiaping Zhou, Senior Vice President and President of Greater China, Novo Nordisk, said: "This investment is an important step for Novo Nordisk to realize the new layout of the 'dual center, three engines' whole industry chain, which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients.
-
"Innovation" has become the main theme of the development of the domestic medical device industry!
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];In recent years, under the promotion of multiple advantages such as encouraging innovative medical devices, marginal easing of centralized procurement policies, and supporting equipment renewal with financial discounted loans, the development of the domestic medical device industry is accelerating.
-
The stock prices of Yiling Pharmaceutical, Northeast Pharmaceutical, Xinhua Pharmaceutical, etc. soared in December!
Time of Update: 2022-12-30
38 yuan per share; Ibuprofen API leader Xinhua Pharmaceutical has gained 8 limit increases in the last 10 trading days.
38 yuan per share; Ibuprofen API leader Xinhua Pharmaceutical has gained 8 limit increases in the last 10 trading days.
-
2022 annual inventory: 70 billion US dollars, a big year for global mergers and acquisitions! Novartis and GSK "interact" frequently, Pfizer 5 times to the bottom of the attempt...
Time of Update: 2022-12-30
The total amount of mergers and acquisitions exceeded $70 billion Pfizer rode the dust The capital winter also accelerates the M&A process between pharmaceutical companies.
The total amount of mergers and acquisitions exceeded $70 billion Pfizer rode the dust The capital winter also accelerates the M&A process between pharmaceutical companies.
-
Under the tide of cooperation between pharmaceutical companies, the development of new drugs is accelerating
Time of Update: 2022-12-30
GenFleet partners with Merck of Germany On December 19, GenFleet announced that it has entered into a European multi-center clinical research and drug supply collaboration agreement with Merck KGaA to conduct a Phase 1b/2 clinical study of GenFleet's combination therapy with KRAS G12C inhibitor GFH925 and Merck's anti-EGFR antibody cetuximab injection to evaluate the effectiveness of this combination therapy in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC).
-
Many pharmaceutical companies suspended! All trading was suspended due to abnormal fluctuations in the rise and fall
Time of Update: 2022-12-30
2 million in the same period in 2021; The net loss in the first quarter of 2022 was approximately RMB14.
2 million in the same period in 2021; The net loss in the first quarter of 2022 was approximately RMB14.
-
mRNA vaccine second half: Moderna has switched to cancer treatment, clinically reducing the risk of recurrence and death by 44%.
Time of Update: 2022-12-30
On October 12, 2022, Merck and Moderna signed a $250 million partnership agreement for the joint development and commercialization of the Personalized Cancer Vaccine (PCV) mRNA-4157/V940 。 On December 13, Moderna's official website announced that the combination of personalized cancer vaccine mRNA-4157/V940 and PD-1 inhibitor Keytruda showed that compared with Keytruda monotherapy, it can significantly reduce the risk of recurrence or death in stage III and IV melanoma patients after complete tumor resection by 44%!
-
Jiangsu: Notice on further strengthening the work of ensuring the supply and price of medical supplies
Time of Update: 2022-12-30
On December 17, the Jiangsu Provincial Market Supervision Bureau and the Food and Drug Administration jointly issued the Notice on Further Strengthening the Work of Ensuring the Supply and Stabilizin
-
Since December, many pharmaceutical companies have encountered setbacks in drug research and development
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];On December 19, AstraZeneca announced that the drug Imfinzi, as a monotherapy for patients with advanced non-small cell lung cancer, failed to achieve its primary goal of improving overall survival compared to platinum-based chemotherapy.
